For the past several weeks, the scientific and longevity communities have been discussing a development sparked by a widely discussed publication in Nature. After years of laboratory promises, a therapy based on cellular reprogramming has finally crossed a technological barrier and entered human testing. We asked Professor Ewelina Pośpiech, an expert in epigenetic aging and Program Director of ELEVATE, to comment on the significance of this step for aging medicine:
Toward the medicine of the future
Professor Ewelina Pośpiech: This is undoubtedly one of the most exciting moments in the biology of aging in recent years. For the first time, a therapy directly targeting the epigenetic mechanisms of aging has entered clinical trials.
Why is this so important? Because for the first time, a concept that had been tested for years only in laboratories and animal models is now being studied in humans. Preclinical studies observed improved tissue function, better regeneration, and the reversal of selected features of aging. In some studies, these effects were also confirmed using epigenetic clocks, which indicated a reduction in the biological age of tissues. Now, for the first time, it will be possible to assess whether this approach is also safe in humans.
The therapy being developed by Life Biosciences uses three of the four classic Yamanaka factors: OCT4, SOX2, and KLF4. For years, the greatest concerns surrounding the use of Yamanaka factors involved the loss of cellular identity and the risk of tumor formation. Using three factors instead of four, together with their controlled and temporary expression, is intended to preserve the beneficial biological effect while significantly reducing the risks associated with complete cellular reprogramming. This is what allowed a strategy that until recently appeared too risky for use in humans to enter clinical trials.
A Phase I study is currently being conducted in patients with optic nerve diseases. Its primary objective is to evaluate the safety of a gene therapy administered locally to the eye. The choice of this tissue is not accidental. It enables precise, localized delivery of the therapy and limits its effects on the rest of the body’s tissues.
This is the first phase of clinical research, whose main objective is to assess safety. However, if the results prove promising, they may open the way to further applications, initially in the treatment of age related diseases and, in the longer term, perhaps also in therapies aimed at improving health and quality of life in later years.
This is only the first step. But it is a step that seemed like a distant vision only a few years ago and is now becoming a reality in clinical research.
A new chapter in longevity
The transition from theory and animal models to the first phase of human trials is a moment the longevity community has been awaiting with great anticipation. As the editorial team of Elevate magazine, we will closely follow the publication of further results from Life Biosciences and continue bringing you the most important insights.
“`
